Table 3.
Subgroup analysis of diagnostic efficacy based on circRNA in differentiating HCC from healthy controls and patients with liver disease.
| Diagnostic techniques | Sensitivity (95%CI) | specificity (95%CI) | Diagnostic odds ratio (95%CI) | Superiority index (95%CI) |
Relative sensitivity (95%CI) |
Relative specificity (95%CI) |
|---|---|---|---|---|---|---|
| Diagnostic performance based on HCC vs. healthy control | ||||||
| hsa_circ_00156 | 0.940 (0.874-0.978) | 0.469 (0.343-0.598) | 13.824 (5.291-36.113) | 0.991 (0.111-5) | 1.000 | 1.000 |
| hsa_circ_000224 | 0.976 (0.931-0.995) | 0.846 (0.695-0.941) | 223.667 (53.085-942.399) | 3.091 (0.143-9) | 1.182 (0.479-2.402) | 1.834 (0.450-6.145) |
| hsa_circ _000520 | 0.969 (0.922-0.991) | 0.889 (0.739-0.969) | 248 (58.796-1046.062) | 2.983 (0.143-9) | 1.423 (0.489-2.358) | 1.924 (0.396-6.630) |
| circSMARCA5 | 0.914 (0.851-0.956) | 0.836 (0.754-0.900) | 54.364 (24.470-120.779) | 2.388 (0.111-9) | 1.15 (0.321-2.972) | 1.967 (0.322-7.619) |
| hsa_circ_0003998 | 0.909 (0.829-0.960) | 0.677 (0.547-0.791) | 21 (8.530-51.702) | 1.887 (0.111-9) | 1.146 (0.302-2.961) | 1.74 (0.262-6.507) |
| Diagnostic performance based on HCC vs. liver disease | ||||||
| circSMARCA5 | 0.794 (0.597-0.909) | 0.750 (0.694-0.799) | 11.587 (2.945-45.584) | 1.322 (0.333-3) | 1.000 | 1.000 |
| hsa_circ_0003998 | 0.847 (0.760-0.912) | 0.673 (0.529-0.797) | 11.392 (5.125-25.324) | 1.336 (0.333-3) | 1.41 (0.277-4.434) | 1.215 (0.206-4.084) |